Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Multiple Myeloma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × crenigacestat × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT03502577 2024-01-08

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡